Studying Anakinra to Reduce Secondary Brain Damage After Spontaneous Haemorrhagic Stroke

Intracerebral Hemorrhage Clinical Trial

— ACTION  

Official title:

Anakinra in Cerebral Haemorrhage to Target Secondary Injury Resulting From Neuroinflammation - a Phase II Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04834388
• Other study ID #: NL76607.091.21
• Status: Recruiting
• Phase: Phase 2
• Start date: August 10, 2022
• Est. completion date: December 2024

Study information

• Verified date: November 2023
• Source: Radboud University Medical Center
• Contact: Floris H.B.M Schreuder, MD PhD
• Phone: +31650155755
• Email: floris.schreuder[@]radboudumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Spontaneous intracerebral haemorrhage (sICH) is the deadliest stroke subtype yearly affecting over 6000 patients in the Netherlands. Treatment options are very limited. Inflammation plays a vital role in the development of sICH-related secondary brain injury (SBI). Within 4 hours after sICH onset, blood components and thrombin induce the release of cytokines and other inflammatory molecules, with subsequent microglial activation, blood brain barrier (BBB) damage and the formation of perihaematomal oedema (PHO). Among the released cytokines, interleukin 1 beta (IL-1β) has a pivotal role. Recombinant human interleukin-1 receptor antagonist (IL-1Ra, anakinra) effectively antagonizes IL-1β through competitive binding to the IL-1 receptor. Anakinra is available for treatment of rheumatoid arthritis, other inflammatory diseases and has been studied in acute sepsis. We hypothesize that anakinra safely reduces SBI after sICH, and that its effect is dose-dependent.

Objective: To determine the effect of high-dose versus low-dose anakinra compared to standard medical management on oedema extension distance (OED) determined with MRI on day 7±1. Second, to study the safety profile of anakinra. Furthermore, to assess its effect on 1) serum inflammatory markers IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts at day 1, 3 and 7 compared to baseline; 2) DCE-MRI measurement of BBB transfer constant (Ktrans) on day 7±1, and; 3) to estimate an effect on functional outcome in patients with sICH.

Study design: Multicentre, prospective, randomized, three-armed (1:1:1) trial with open label treatment and blinded end-point assessment (PROBE design) .

Study population: 75 patients with supratentorial sICH admitted within 8 hours after symptom onset.

Intervention: Patients will receive anakinra in either a high dose (loading dose 500mg i.v., followed by infusion with 2mg/kg/h over 3 days; n=25) or in a low dose (loading dose 100mg s.c.., followed by subcutaneous administration of 100mg twice a day for 3 days; n=25), started within 8 hours of symptom onset. The control group (n=25) will receive standard medical management.

Main study parameters/endpoints: Primary objective is to test whether anakinra reduces subacute perihaematomal oedema after sICH, measured as OED on MRI at day 7±1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: December 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years;

2. Supratentorial non-traumatic ICH confirmed by CT, without a confirmed causative lesion on admission CT-angiography (e.g. aneurysm, AVM, DAVF, cerebral venous sinus thrombosis) or other known underlying lesion (e.g. tumour, cavernoma);

3. Minimal intracerebral haemorrhage volume of 10 mL;

4. Intervention can be started within 8 hours from symptoms onset;

5. Patient's or legal representative's informed consent.

Exclusion Criteria:

1. Severe ICH, unlikely to survive the first 72 hours (defined as Glasgow Coma Scale score < 6 at time of consent);

2. Confirmed or suspected haemorrhagic transformation of an arterial or venous infarct;

3. Planned neurosurgical haematoma evacuation;

4. Severe infection at admission, requiring antibiotic treatment;

5. Known active tuberculosis or active hepatitis;

6. Use of immunosuppressive or immune-modulating therapy at admission (see 15.1 Appendix A);

7. Neutropenia (Absolute Neutrophil Count (ANC) <1.5 x 109/L );

8. Pre-stroke modified Rankin Scale score = 3;

9. Pregnancy or breast-feeding;

10. Standard contraindications to MRI (see 15.2 Appendix B);

11. Known prior allergic reaction to gadolinium contrast or one of the constituents of its solution for administration;

12. Known allergy to anakinra or other products that are produced by DNA technology using the micro-organism E. coli;

13. Live vaccinations within the last 10 days prior to this ICH;

14. Severe renal impairment (eGFR <30ml/min/1.73m)

15. Active malignancy

Related Conditions & MeSH terms

• Cerebral Hemorrhage
• Hemorrhage
• Intracerebral Hemorrhage

Intervention

Drug:
• Anakinra
Anakinra treatment is started within 8 hours of symptom onset

Locations

Country	Name	City	State
Netherlands	Radboudumc	Nijmegen

Sponsors (2)

Lead Sponsor	Collaborator
Radboud University Medical Center	Dutch Heart Foundation

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Cliteur MP, van der Kolk AG, Hannink G, Hofmeijer J, Jolink W, Klijn C, Schreuder F. Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial. Eur Stroke J. 2023 Sep 15:23969873231200686. doi: 10.1177/23969873231200686. Online ahead of print. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perihematomal oedema	Measured as Oedema Extension Distance (OED/EED)	7 days after ICH onset
Secondary	Adverse events of special interest (AESI) and serious adverse events (SAE)		90 days
Secondary	Blood brain barriere leakage	Measured as Ktrans on DCE-MRI	7 days
Secondary	Levels of serum inflammatory markers	IL-1ß, IL-6, hsCRP, neutrophil and total white blood cell counts	7 days
Secondary	Functional outcome	Ordinal shift in functional outcome (comparing the intervention group to the controls), assessed with the modified Rankin Scale (mRS) at 3 months. This is a six point scale in which a score of 0 means no symptoms at all, a higher score means more impairment, and a score of 6 means the participant is dead.	90 days

External Links

•   trial website